Copy/Paste the key inputs from the product brochure, per guidance from Solutions.
Osteoarthritic (OA) pain is a prevalent subtype of chronic pain, affecting more than 43 million individuals in the EU5. OA pain treatment decisions are driven primarily by rheumatologists, orthopedics (in Germany), and pain specialists while general practitioners play an important role in long-term disease management. A variety of analgesic drug classes, containing both branded and generic agents, as well as surgical interventions are available for the treatment of OA pain. However, due to variability in patient response and disease progression, patients struggle to attain adequate analgesia without the introduction of intrusive side effects (e.g., cardiovascular events, tolerance, dependence), which also leads to high rates of polypharmacy. Currently, treatment revolves around the use of generic nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid-containing products, but physicians indicate the need for efficacious drugs that are not associated with safety and tolerability issues.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.
Markets covered: France, Germany, Italy, Spain, United Kingdom
Primary research: Survey of 25 pain specialists and 25 rheumatologists in each EU5 country
Key companies: Mundipharma, Grünenthal, Sanofi, Janssen, Pfizer, Novartis
Key drugs covered: Buprenorphine patch, diclofenac topical gel, etoricoxib, hyaluronic acid injection, Palexia Retard/SR, Vimovo
Key insights provided: